Neo Ivy Capital Management Makes New Investment in West Pharmaceutical Services, Inc. $WST

Key Points

• Neo Ivy Capital initiated a new position in West Pharmaceutical (NYSE:WST), acquiring 6,820 shares worth about $1.79M, and institutional investors now own roughly 93.90% of the company with Vanguard, State Street and Artisan among the largest holders.
• Analysts have an average rating of Buy with an average target price of $314.56, although firm-level targets are mixed — Barclays cut its target to $265 while UBS and Evercore remain more constructive.
• Recent operational catalysts include a quarterly EPS beat ($2.04 vs. $1.83), FY2026 guidance of 7.85–8.20 EPS, a newly authorized $1.00 billion share repurchase (up to 5.6% of shares) and a quarterly dividend of $0.22.

Neo Ivy Capital Management acquired a new position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,820 shares of the medical instruments supplier's stock, valued at approximately $1,789,000.

Several other institutional investors and hedge funds also recently made changes to their positions in WST. Vanguard Group Inc. boosted its position in West Pharmaceutical Services by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,704,948 shares of the medical instruments supplier's stock valued at $2,545,899,000 after buying an additional 388,144 shares during the period. State Street Corp boosted its holdings in West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier's stock valued at $715,884,000 after acquiring an additional 68,330 shares during the period. Artisan Partners Limited Partnership grew its position in West Pharmaceutical Services by 22.2% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier's stock worth $726,895,000 after acquiring an additional 503,601 shares during the last quarter. Generation Investment Management LLP purchased a new position in West Pharmaceutical Services in the 2nd quarter worth approximately $255,072,000. Finally, Invesco Ltd. lifted its position in West Pharmaceutical Services by 1.1% in the second quarter. Invesco Ltd. now owns 959,525 shares of the medical instruments supplier's stock valued at $209,944,000 after purchasing an additional 10,070 shares during the last quarter. Institutional investors own 93.90% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on WST. Weiss Ratings reaffirmed a "hold (c)" rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Barclays dropped their price target on shares of West Pharmaceutical Services from $325.00 to $265.00 and set an "equal weight" rating for the company in a research report on Friday, February 13th. Evercore cut their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an "outperform" rating on the stock in a report on Tuesday, February 3rd. UBS Group restated a "buy" rating and issued a $340.00 price objective on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Finally, Zacks Research raised shares of West Pharmaceutical Services from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, January 21st. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $314.56.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a "Strong‑Buy" rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West's own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts' models can change and represent expectations, not guarantees.

West Pharmaceutical Services Price Performance

WST opened at $245.92 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. The stock has a market capitalization of $17.71 billion, a PE ratio of 36.22, a price-to-earnings-growth ratio of 2.59 and a beta of 1.17. The stock's 50 day moving average price is $253.72 and its 200-day moving average price is $262.03. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $322.34.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.21. The company had revenue of $805.00 million during the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm's revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.82 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services's dividend payout ratio (DPR) is currently 12.96%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.